Pyrrolylalkylidene-hydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands
AssigneeWyeth
InventorsMichael Gerard Kelly, Ping Zhou
Life of this patent
Estimating the term…
Abstract
The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.
Claims20
A compound of formula I
- wherein
- Q is SO2, CO, CH2, CO2, CONH or CSNH;
- R1, R2, R3 and R4 are each independently H or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C10cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted or R1 and R2 may be taken together with the atoms to which they are attached to form a 5-, 6- or 7-membered ring;
- R5 is H or R4 and R5 may be taken together with the atoms to which they are attached to form a 5-, 6- or 7-membered ring;
- R6 is a C1-C6alkyl, aryl or heteroaryl group each optionally substituted;
- R7 is H, halogen, NO2, CN, OR8, NR9R10, OCO2R11, OCONR12R13, CO2R14, COR15, CONR16R17 or SO2NR18R19 or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
- R8, R11, R14 and R15 are each independently H or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
- and
- R9, R10, R12, R13, R16, R17, R18 and R19 are each independently H or an optionally substituted C1-C6alkyl group or R9 and R10 may be taken together with the atom to which they are attached to form a 5-, 6- or 7-membered ring optionally containing another heteroatom selected from O, N or S;
- or
- the stereoisomers thereof or the pharmaceutically acceptable salts thereof.
The compound according to 4 wherein R4 is H or CH3 and R5 is H.
A method for the treatment of a disorder of the central nervous system related to or affected by the 5-HT6 receptor wherein said disorder is selected from the group consisting of motor disorder, anxiety disorder, cognitive disorder, schizophrenia, depression, Alzheimer's disease, Parkinson's disease, attention deficit disorder and obsessive compulsive disorder, in a patient in need thereof which comprises providing to said patient a therapeutically effective amount of a compound of formula I
- wherein
- Q is SO2, CO, CH2, CO2, CONH or CSNH;
- R1, R2, R3 and R4 are each independently H or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C10cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted or R1 and R2 may be taken together with the atoms to which they are attached to form a 5-, 6- or 7-membered ring;
- R5 is H or R4 and R5 may be taken together with the atoms to which they are attached to form a 5-, 6- or 7-membered ring;
- R6 is a C1-C6alkyl, aryl or heteroaryl group each optionally substituted;
- R7 is H, halogen, NO2, CN, OR8, NR9R10, OCO2R11, OCONR12R13, CO2R14, COR15, CONR16R17 or SO2NR18R19 or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
- R8, R11, R14 and R15 are each independently H or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
- and
- R9, R10, R12, R13, R16, R17, R18 and R19 are each independently H or an optionally substituted C1-C6alkyl group or R9 and R10 may be taken together with the atom to which they are attached to form a 5-, 6- or 7-membered ring optionally containing another heteroatom selected from O, N or S;
- or
- the stereoisomers thereof or the pharmaceutically acceptable salts thereof.
A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an effective amount of a compound of formula I
- wherein
- Q is SO2, CO, CH2, CO2, CONH or CSNH;
- R1, R2, R3 and R4 are each independently H or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C10cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted or R1 and R2 may be taken together with the atoms to which they are attached to form a 5-, 6- or 7-membered ring;
- R5 is H or R4 and R5 may be taken together with the atoms to which they are attached to form a 5-, 6- or 7-membered ring;
- R6 is a C1-C6alkyl, aryl or heteroaryl group each optionally substituted;
- R7 is H, halogen, NO2, CN, OR8, NR9R10, OCO2R11, OCONR12R13, CO2R14, COR15, CONR16R17 or SO2NR18R19 or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
- R8, R11, R14 and R15 are each independently H or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
- and
- R9, R10, R12, R13, R16, R17, R18 and R19 are each independently H or an optionally substituted C1-C6alkyl group or R9 and R10 may be taken together with the atom to which they are attached to form a 5-, 6- or 7-membered ring optionally containing another heteroatom selected from O, N or S;
- or
- the stereoisomers thereof or the pharmaceutically acceptable salts thereof.
A process for the preparation of a compound of formula I
- wherein
- Q is SO2, CO, CH2, CO2, CONH or CSNH;
- R1, R2, R3 and R4 are each independently H or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C10cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted or R1 and R2 may be taken together with the atoms to which they are attached to form a-5-, 6- or 7-membered ring;
- R5 is H or R4 and R5 may be taken together with the atoms to which they are attached to form a 5-, 6- or 7-membered ring;
- R6 is a C1-C6alkyl, aryl or heteroaryl group each optionally substituted;
- R7 is H, halogen, NO2, CN, OR8, NR9R10, OCO2R11, OCONR12R13, CO2R14, COR15, CONR16R17 or SO2NR18R19 or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
- R8, R11, R14 and R15 are each independently H or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
- and
- R9, R10, R12, R13, R16, R17, R18 and R19 are each independently H or an optionally substituted C1-C6alkyl group or R9 and R10 may be taken together with the atom to which they are attached to form a 5-, 6- or 7-membered ring optionally containing another heteroatom selected from O, N or S
- which process comprises reacting a compound of formula
- wherein Q, R4, R5, R6 and R7 are as described hereinabove with an aminoguanidine of formula IV
- wherein R1, R2 and R3 are described hereinabove in the presence of an acid optionally in the presence of a solvent.
Dependencies are inferred from the claim text.